Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY25 results · Jul–Sep 2024
Eris Lifesciences reported revenue from operations of ₹738.95 crore (up 46.2% from Q2 FY24) and net profit of ₹96.35 crore (down 21.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 738.95 | 505.30 | +46.2% | 719.72 | +2.7% |
| Other income | 6.77 | 3.48 | +94.5% | 1.64 | +312.8% |
| Total income | 745.72 | 508.78 | +46.6% | 721.36 | +3.4% |
| Profit before tax | 129.11 | 126.24 | +2.3% | 115.32 | +12.0% |
| Net profit for the period | 96.35 | 122.31 | −21.2% | 89.42 | +7.8% |
| Attributable to shareholders of the company | 91.59 | 123.43 | −25.8% | 83.18 | +10.1% |
| EPS, basic (₹) | 6.73 | 9.08 | −25.9% | 6.11 | +10.1% |
| Net margin (%) | 13.0 | 24.2 | 12.4 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 428.75 | 409.71 | +4.6% | 456.69 | −6.1% |
| Other income | 13.62 | 6.97 | +95.3% | 5.16 | +164.0% |
| Total income | 442.37 | 416.68 | +6.2% | 461.85 | −4.2% |
| Profit before tax | 46.02 | 119.92 | −61.6% | 26.82 | +71.6% |
| Net profit for the period | 28.10 | 117.81 | −76.1% | 17.04 | +64.9% |
| EPS, basic (₹) | 2.06 | 8.66 | −76.2% | 1.25 | not comparable |
| Net margin (%) | 6.6 | 28.8 | 3.7 |
Consolidated
- Filed with BSE
- 28 Oct 2024, 11:52 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Oct 2024, 11:52 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE